8th Feb 2005 14:15
Pfizer Cancer Drug Demonstrates Early Efficacy and Safety; Placebo Patients to Switch Immediately to Drug Therapy NEW YORK, Feb. 8 -- Pfizer Inc said today that a Phase III study of SU11248, a cancer medicine being developed to treat Gleevec(R) -- resistant gastrointestinal stromal tumor (GIST), has demonstrated efficacy and safety seven months ahead of schedule. Because of these positive results, an independent panel of experts has recommended stopping the trial. Patients who have received placebo are being given the option of switching to SU11248. SU11248 is a novel, oral multi-targeted cancer therapy that combines anti-angiogenic and anti-tumor activity to simultaneously stop the blood supply to and directly attack tumor cells. "We are encouraged by this interim data analysis and believe this is a positive step towards establishing SU11248 as an option for patients with Gleevec-resistant GIST," said Dr. Joseph Feczko, Pfizer president of worldwide development. "Pfizer and study investigators are working together to provide SU11248 to those enrolled in the study as quickly as possible and hope this unique therapy will continue to provide meaningful clinical benefit for cancer patients." SU11248 also is being studied in Phase III trials as a potential treatment for renal cell carcinoma. DISCLOSURE NOTICE: The information contained in this document is as of February 8, 2004. Pfizer assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking information about a product candidate that involves inherent risks and uncertainties. Such risks and uncertainties include, among other things, the speed with which regulatory authorizations for and the launch of the product may be achieved, and competitive developments, among other factors, that could affect the commercial potential of such product. A further list and description of these risks, uncertainties and other matters can be found in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2003, and in its periodic reports on Forms 10-Q and 8-K. SOURCE Pfizer Inc 02/08/2005 /CONTACT: Susan Bro of Pfizer Inc, +1-212-733-5554/ /Company News On-Call: http://www.prnewswire.com/comp/688250.html / /Company News On-Call: Pfizer's press releases are available through PR Newswire's Company News On-Call service on PRN's Web Site. Visit http://www.prnewswire.com/comp/688250.html/ /Photo: A free corporate logo to accompany this story is available immediately via Wieck Photo Database to any media with telephoto receiver or electronic darkroom, PC or Macintosh, that can accept overhead transmissions. To retrieve a logo, please call 972-392-0888./ /Web site: http://www.pfizer.com / (PFE) ENDRelated Shares:
PFZ.L